Given the potential importance of NUAK1 in the phosphorylation of tau at Ser356, and our findings that p-tau Ser356 is highly associated with disease progression in AD, we sought to characterise the impacts of pharmacological NUAK inhibition under a range of physiological and disease-model conditions. Here, MAPT is linked to Alzheimer disease.